Nagaya T, Niwa S, Harada S, Konishi Y
Department of Orthopedic Surgery, Nagoya National Hospital.
Drugs. 1988;35 Suppl 1:101-6. doi: 10.2165/00003495-198800351-00023.
In a multicentre trial, tiaprofenic acid was administered in a dosage of 600 mg/day for 12 months to 109 patients with rheumatoid arthritis. The results in 79 patients, who did not receive any other non-steroidal anti-inflammatory drugs concomitantly, were assessed. Of the 79 patients, 11 withdrew from the study within one year. The reasons for withdrawal were personal reasons in 4 cases, side effects or abnormal laboratory values in 2, no change or aggravation of symptoms in 2, improvement of symptoms in 2, and identification of systemic lupus erythematosus in one. Overall improvement was definite in 27 patients (34.2%) and slight in 21 patients (26.6%). Overall usefulness was definite in 30 patients (38%) and slight in 27 patients (34.2%). The duration of morning stiffness, joint index and Lansbury activity index showed significant improvement after 6 months' administration. Side effects were observed in 2 cases (2.5%) and abnormal laboratory results were seen in 3 (3.8%). These disappeared on either continuation or discontinuation of treatment.
在一项多中心试验中，对109例类风湿性关节炎患者给予噻洛芬酸，剂量为600毫克/天，持续12个月。评估了79例未同时接受任何其他非甾体抗炎药治疗的患者的结果。在这79例患者中，有11例在一年内退出研究。退出原因分别为：4例是个人原因，2例是副作用或实验室检查值异常，2例是症状无变化或加重，2例是症状改善，1例是确诊为系统性红斑狼疮。27例患者（34.2%）有明确的总体改善，21例患者（26.6%）有轻微改善。30例患者（38%）有明确的总体疗效，27例患者（34.2%）有轻微疗效。给药6个月后，晨僵持续时间、关节指数和兰斯伯里活动指数均有显著改善。观察到2例（2.5%）出现副作用，3例（3.8%）出现实验室检查结果异常。这些在继续治疗或停止治疗后均消失。
